Drugs / Gelafundin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06900972 | Apr → Aug 2025 overdue | — | University of Monastir | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06180824 Comparator | Jan → Dec 2024 | hyperglycemia | Universiti Sains Malaysia | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gelafundin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06900972 ↗ |